NEW ISSUE
State-of-the-Art on Coronary Physiology; a Mini Focus on Biostatistics; Post-TAVI Aortic Manipulation; Minimally Invasive Ventricular Reconstruction after MI
April 2, 2021
Showing 1-14 of 14 articles
A multicentre, randomised controlled clinical study of drug-coated balloons for the treatment of coronary in-stent restenosis
July 17, 2020 | 10.4244/EIJ-D-19-00051
Interventions for valvular disease
Final results from the REPRISE I study: five-year clinical outcomes with the repositionable and fully retrievable LOTUS valve system December 7, 2018 | 10.4244/EIJ-D-18-00664
Final five-year clinical outcomes in the EVOLVE trial: a randomised evaluation of a novel bioabsorbable polymer-coated, everolimus-eluting stent
April 20, 2018 | 10.4244/EIJ-D-17-00529
A randomised comparison of biodegradable polymer- and permanent polymer-coated platinum-chromium everolimus-eluting coronary stents in China: the EVOLVE China study
November 20, 2017 | 10.4244/EIJ-D-17-00271
Interventions for valvular disease
Repositionable percutaneous aortic valve implantation with the LOTUS valve: 30-day and 1-year outcomes in 250 high-risk surgical patients September 20, 2017 | 10.4244/EIJ-D-16-01024
Interventions for valvular disease
Insights into the need for permanent pacemaker following implantation of the repositionable LOTUS valve for transcatheter aortic valve replacement in 250 patients: results from the REPRISE II trial with extended cohort September 20, 2017 | 10.4244/EIJ-D-16-01025
Transfemoral aortic valve replacement with the repositionable Lotus Valve System in high surgical risk patients: the REPRISE I study
March 20, 2014 | 10.4244/EIJV9I11A216
Boston Scientific Lotus valve
September 30, 2012 | 10.4244/EIJV8SQA12